Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype, Oncogene, vol.11, pp.1363-74, 1989. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-54, 2002. ,
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis, Br J Dermatol, vol.164, pp.776-84, 2011. ,
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression, Clin Cancer Res, vol.9, pp.6483-6491, 2003. ,
BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival, J Invest Dermatol, vol.125, pp.312-319, 2005. ,
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma, J Clin Oncol, vol.29, pp.1239-1285, 2011. ,
Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma, J Mol Diagn, vol.15, pp.220-226, 2013. ,
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models, Cancer Res, vol.70, pp.5518-5545, 2010. ,
Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, vol.363, pp.809-828, 2010. ,
BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, pp.2507-2523, 2011. ,
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, pp.707-721, 2012. ,
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.380, pp.358-65, 2012. ,
Tumor adaptation and resistance to RAF inhibitors, Nat Med, vol.19, pp.1401-1410, 2013. ,
BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma, Melanoma Res, vol.24, pp.415-423, 2014. ,
BRAF and c-kit gene copy number in mutation-positive malignant melanoma, Hum Pathol, vol.37, pp.520-527, 2006. ,
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.480, pp.387-90, 2011. ,
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, pp.94-100, 2013. ,
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinicalformalin fixed paraffin embedded samples, Exp Mol Pathol, vol.92, pp.275-80, 2012. ,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)), Method Methods, vol.25, pp.402-410, 2001. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1753, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease, Blood, vol.124, pp.3016-3025, 2014. ,
Prognostic value of BRAFV600 mutations inmelanoma patients after resection of metastatic lymph nodes, Ann SurgOncol, vol.19, pp.4314-4335, 2012. ,
Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility, Arch Pathol Lab Med, vol.138, pp.71-76, 2014. ,
Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression, Endocr Relat Cancer, vol.21, pp.891-902, 2014. ,
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma, J Mol Diagn, vol.9, pp.464-71, 2007. ,
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, vol.464, pp.427-457, 2010. ,
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032, J Transl Med, vol.8, p.39, 2010. ,
Intra-and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma, PLoS One, vol.7, p.29336, 2012. ,
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, Br J Cancer, vol.108, pp.924-955, 2013. ,
Distinct sets of genetic alterations in melanoma, N Engl J Med, vol.353, pp.2135-2182, 2005. ,
Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines, Genes Chromosomes Cancer, vol.48, pp.419-447, 2009. ,
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays, Cancer Res, vol.67, pp.2632-2674, 2007. ,
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH, Oncogene, vol.26, pp.4738-4786, 2007. ,
Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study, Genes Chromosomes Cancer, vol.49, pp.733-778, 2010. ,
Determinants of BRAF mutations in primary melanomas, J Natl Cancer Inst, vol.95, pp.1878-90, 2003. ,
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am J Surg Pathol, vol.37, pp.61-66, 2013. ,
High frequency of BRAF mutations in nevi, Nat Genet, vol.33, pp.19-20, 2003. ,
Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool, Dermatol Ther, vol.19, pp.40-49, 2006. ,